Clinical Evaluation of Medical Devices

A Clinical Evaluation is far more than just a summary of literature. It is a stringent line of argument that must demonstrate that your product is safe and achieves its intended clinical benefit. In the MDR era, it has become the critical path for every market authorization.

My Approach: Methodical. Transparent. Resilient.

Scoping & Strategy:

- Definition of the Intended Use and Clinical Benefit

- Description of the State of the Art (SOTA) and Performance and Safety Parameters

- Precise selection of Comparator Devices as Equivalents or Benchmarks

Systematic Literature and Database Search

Execution and documentation in accordance with established scientific standards.

Data Analysis and Appraisal:

Critical appraisal of clinical and pre-clinical data, accounting for bias and relevance.

Demonstration of Conformity:

Consolidation of all findings into a consistent and contradiction-free line of argument.

Your Advantage

Track Record of 70+ CERs: A success rate of over 95% with no significant deficiencies raised by Notified Bodies.
Efficiency through Methodology: By focusing on a resilient line of argument, my average turnaround time is only about 10 man-days.
Reviewer Perspective: I am intimately familiar with the assessment criteria of Notified Bodies from practical experience, allowing me to avoid unnecessary correction loops.

FAQ

What is a Clinical Evaluation and how do we proceed methodically?

At its core, a clinical evaluation is a gap analysis for a medical device. The 'Target' is typically defined by the State of the Art (SOTA), while the 'Actual' is evidenced by the specific data of your medical device.

Our collaboration aims to bridge this gap—not just in theory, but by establishing a sound line of argument. The result is a clear and resilient conformity assessment that proactively addresses the rigorous scrutiny of Notified Bodies.

What is the significance of the Clinical Evaluation Plan (CEP)?

While the formal framework of the Clinical Evaluation Plan (CEP) is strictly defined in Annex XIV of the MDR, this only provides the structure. It does not dictate the individual argumentation strategy, which is the decisive factor for a successful conformity assessment by the Notified Body.

In practice, Clinical Evaluations are often finalized toward the end of product development. Our core task lies in the methodical synthesis: by combining the existing data ('Actual') with the 'Target' derived from the State of the Art, we develop a self-contained strategy. Only through such expert processing can a plan emerge that both satisfies formal requirements and builds a cohesive argumentative bridge to market authorization.

Which data can be used for the medical device being evaluated?

In accordance with MDR Annex XIV, Section 4, clinical data may be used in conjunction with non-clinical data from bench testing and other relevant documentation to demonstrate conformity with the General Safety and Performance Requirements (GSPR). Critically, this evaluation must account for both positive and negative results.

Together, we will specifically identify the data that most strongly support the safety and performance of your product. Critical or negative findings are precisely contextualized within the current State of the Art. The ultimate goal is a resilient risk-benefit argument that withstands regulatory scrutiny and provides definitive proof of conformity.

Are purely non-clinical data sufficient for authorization?

The simple answer is YES. Article 61(10) of the MDR explicitly allows for this possibility. However, in such cases, the manufacturer must provide a robust justification within the Clinical Evaluation, proving that clinical data is not required or cannot be obtained to demonstrate that the device safely performs its intended function.

Ideally, we establish this argumentative strategy at the very beginning of the development process and pursue it consistently. We ensure that both the intended purpose and clinical benefit are defined with such precision that this pathway remains transparent and acceptable to the Notified Body.

Why is the definition of Safety and Performance Parameters so critical?

The definition of these parameters is the 'meter stick' of your evaluation. Without precisely defined, measurable criteria, it is impossible to objectively prove that your device is safe and effective. In the eyes of a Notified Body, vague parameters are the primary indicator of a weak clinical strategy.

Together, we define product-specific parameters that satisfy high regulatory standards while remaining realistically demonstrable for your device.

What makes an effective PMCF Plan (Post-Market Clinical Follow-up)?

While the formal requirements for a PMCF plan are detailed in MDCG 2020-7, its true value lies in its function as a tactical tool. The plan must define and commit to specific measures designed to close any data gaps identified during the clinical evaluation process. In cases where no immediate gaps are apparent, these measures serve as an 'early warning system' to detect—and ideally resolve—emerging questions regarding the safety and performance of the device as it is used in the real world.

In our collaboration, we do not create a ‘plan for the drawer,’ but a pragmatic strategy that defines exactly the measures necessary for your product—no more and no less. This saves time and avoids unnecessary resource expenditure in the post-market phase.

When is the optimal time to start the Clinical Evaluation?

Ideally, you should start with the very first product idea. By starting early, we interlock the Clinical Evaluation directly with your engineers' User Requirements Specifications (URS) and System Requirements Specifications (SRS)

Together, we prevent your clinical department from operating in a ‘parallel universe.’ By ensuring a seamless flow of information, we make sure that no valuable data is lost — protecting you from being blindsided by expensive, time-consuming demands for additional clinical trials just before your scheduled market launch.